Product Interview Q&Aby Vishal Builds
HealthcareSeniorSegmentation-axis pivot (funnel-stage dead end → category → user-type) + decisiveness under thin data

Order completion rate at 1mg has plateaued. How would you improve it?

1mg sells across categories: prescription (Rx) and over-the-counter (OTC) medicines, diagnostics, teleconsultation, wellness and devices. Order completion has been flat for a while, with no known trigger and thin instrumentation.

New to these cases? Read the method first: S&O Framework

Clarify scope and constraints

Before I reach for a lever, I need to know what actually dropped, and what data I'm working with.

Candidate

Is this a recent drop, or a standing plateau?

Interviewer

Standing, it's been stable-low for a while. Nothing changed, no redesign, no competitor move, no pricing change.

Candidate

Chronic, nothing changed, so this is an optimisation problem, not an incident I need to diagnose. Second: 1mg sells across categories, medicines, diagnostics, teleconsultation, devices, wellness. Is 'order completion' the whole platform, or specifically medicine orders?

Interviewer

Scope it to medicine orders, both Rx and OTC. Diagnostics and teleconsultation are separate funnels with their own numbers.

Candidate

Good, that's the right boundary. A lab-test booking and a vitamin purchase don't share a completion problem, so averaging across them would hide more than it reveals. Last: what data do we actually have?

Interviewer

Not much granular instrumentation. Basic order attributes like prescription-required or not are tracked. Stage-by-stage drop-off, browse to cart to checkout to payment, looks about the same as it has always been, nothing stage-specific stands out.

Agree the real objective and guardrails

Raw "order completed" is the wrong target here, this is medicine, so a completed-but-wrong order is worse than no order at all.

Candidate

Do we track orders that complete but then get cancelled or rejected, wrong prescription match, dosage issue, pharmacist rejection after the fact?

Interviewer

Yes, separately. It's not been part of how this metric is judged so far.

Candidate

It should be. The real objective is orders that complete AND are actually fulfilled, not rejected or cancelled after the fact. So I'd track completion alongside pharmacist-rejection rate and CS ticket volume as guardrails, so I don't push a fix that completes more orders by being careless with a safety-critical product.

Segment to find the actual leak

Stage-level drop-off is uniform, so that axis is a dead end, the same signal I'd read in any funnel: if one step were broken I'd expect a spike there relative to the rest, and there isn't one. With thin instrumentation I shouldn't expect a re-ask to suddenly produce a clean breakdown either. So I'd pivot the axis, not where in the funnel, but what kind of order, and then who.

Candidate

Medicine orders split into prescription-required (Rx) and over-the-counter (OTC). Can I get completion by that cut?

Interviewer

OTC completes around 70%. Rx completes around 45%.

Candidate

That's the real gap, it was sitting inside the blended average the whole time. Now, within Rx specifically: is there a difference between someone re-ordering a medication they already take monthly, versus someone uploading a prescription for a new or first-time condition?

Interviewer

No clean split, but pharmacist-verification queries and support contacts skew heavily toward first-time uploads, not repeat refills.

Candidate

That fits the pattern. Someone refilling their monthly BP medication for the fifth time has zero uncertainty and converts about as well as an OTC buyer. Someone uploading a new prescription is uncertain about the exact medicine, the dosage, whether a generic substitute is safe, and whether it'll even be approved, and that uncertainty taxes every stage a little rather than breaking one visibly. That's exactly why it never showed up as a stage-specific spike, and exactly why the Rx-versus-OTC cut had to come first before the new-versus-repeat cut inside Rx could mean anything.

Map the levers for that segment

Given the signal points at first-time, new-condition Rx buyers, the causes bucket into three:

Uncertainty about correctness. Is this the right medicine and dosage, is a generic substitute safe, will it even be approved. A first-timer has no prior experience to anchor on.

Invisible verification. The order sits in pharmacist review with no visibility into status or timeline, which reads as limbo, not progress, to someone who's never been through this flow before.

Proxy-buying complexity. A meaningful share of new prescriptions are uploaded on behalf of a parent or dependent, where the buyer doesn't know all the details themselves and hesitates to commit without confirming.

The interviewer pushes back

Interviewer

You're building a whole segment story off a handful of support tickets. How do you know this is actually where the volume or opportunity is, not just where the loudest complaints are?

Candidate

Fair, and I wouldn't bet the whole roadmap on it. Two things. One, I'd get a real read cheaply: tag orders with a simple is-first-time-prescription flag this week, barely any engineering, one field, and compare completion for a week before committing further. Two, and this is why I'm comfortable moving now rather than waiting on that data: every fix I'd propose for this segment is low-regret even if my read is partly wrong. Showing verification status instead of silence, or explaining generic substitution, doesn't hurt repeat-refill customers, it just does nothing for them. So I'm not gambling the roadmap on a guess, I'm making cheap, safe bets while the tag confirms or kills the story within a week.

Solutions, ranked, and what I'd deprioritise

Impact against effort, all targeted at the first-time-Rx segment specifically:

Do first (cheap, content or policy only, ships fastest):

  1. Live verification status. "Your prescription is being reviewed, typically 20 minutes" instead of silence.
  2. A "what happens next" timeline shown right after upload. Review, then substitution check if needed, then confirm, then payment. Distinct from live status, this orients a first-timer who's never seen the flow before, rather than updating them mid-wait.
  3. Real-time upload-quality check. Flag a blurry photo, a missing doctor signature, or unclear dosage at the moment of upload, not after a wait that ends in rejection. This kills the worst version of the problem, waiting through verification just to be told to start over.

Do next (light ops or backend, still segment-targeted):

  1. Generic-versus-branded explainer, shown only on first-time uploads.
  2. A one-tap confirm-and-reassure step before payment. "Approved, matches your prescription exactly" or "Substituted with a same-salt generic, here's why," right at the moment uncertainty peaks, just before money is committed.
  3. An explicit "we'll call you before substituting or rejecting" promise. Cheap to state, but needs a real process behind it so it's actually true. Targets the "will this silently be the wrong thing" fear directly.

Later, higher-effort (ops-heavy, highest-touch for the hardest cases):

  1. Proactive pharmacist chat prompt, triggered specifically on first-time uploads, offering to confirm dosage or substitution before the customer has to wonder and abandon.
  2. Assisted WhatsApp or call upload, specifically for proxy buyers uploading a parent's or dependent's prescription, who often don't know the full details themselves.

Compounding, not a fix for this order:

  1. Save a verified prescription for effortless future refills. Doesn't move this order's completion, but converts a first-timer into a repeat customer faster on their next order, shrinking the problem segment over time. Worth doing, wrong to count as this metric's fix.

What I'd explicitly deprioritise: silent auto-substitution with no visible confirmation. It's tempting, it removes a step and speeds completion, but it strips out exactly the moment that builds trust for an uncertain first-time buyer, and it's a direct risk to the pharmacist-mismatch guardrail. I'd also skip a broad checkout redesign and blanket discounts, the data says the funnel isn't broken at a visible step and repeat-refill customers already convert fine, so neither would move the number that actually leaks.

Sequence and measure

Sequence: ship the first-time-prescription tag this week, cheap instrumentation that confirms or kills the read fast. In parallel, ship the live status, the "what happens next" timeline, and the upload-quality check, all safe regardless of how the tag lands. Next, the substitution explainer and the pre-payment confirm step. Later, the pharmacist chat prompt and assisted upload once ops can support them, and the save-prescription feature as a compounding, not urgent, follow-up.

Measured in three layers:

  • Leading indicators: completion rate specifically among tagged first-time-prescription orders, and time-to-verification.
  • Lagging headline: overall medicine order completion rate.
  • Guardrails: pharmacist-rejection and cancellation rate, CS ticket volume.

If the tagged first-time cohort's completion doesn't move, the segment read was wrong, and I'd re-cut rather than keep shipping further down this list.

Risks, and how I would de-risk

Proactive pharmacist chat could overload verification staff. De-risk: make it async, not a mandatory call, and cap volume until it's proven.

The segmentation guess could be wrong. De-risk: this is exactly why the first tier of fixes is cheap and harmless to repeat-refill customers, being wrong costs almost nothing.

A "we'll call before substituting" promise that isn't operationally true erodes trust worse than saying nothing. De-risk: only ship that messaging once the process behind it is real.

One-line close

So: a uniformly flat funnel with thin data ruled out a broken step, but a category cut the blended average was hiding, Rx versus OTC, and a user-type cut inside Rx, first-time versus repeat, found where the real leak lives. I'd ship cheap, segment-targeted fixes for first-time prescription uncertainty first, confirm the read with a one-field tag rather than waiting on data that doesn't exist, and protect pharmacist-safety guardrails throughout.

For the candidate

Keep in mind

  • Fix the category boundary before touching the funnel; 1mg isn't one product, and averaging medicine, diagnostics, and teleconsultation into one completion number hides more than it reveals.
  • Reframe the objective to orders that complete AND are fulfilled, not raw completion, whenever a completed-but-wrong outcome is worse than no order.
  • When stage-level drop-off is uniform, pivot the segmentation axis: category first (Rx vs OTC), then user-type within the segment that leaks (first-time vs repeat).
  • Under a thin-data challenge, name the cheapest test that would confirm or kill your segment story, and argue your fixes are safe even if the read is imperfect, decisiveness without demanding data that does not exist.
  • Rank the full solution set and still name what you'd cut; the tempting shortcut (auto-substitution, here) is usually the one that removes the exact thing the uncertain segment needs.
  • Close on layered metrics: a leading read on the tagged segment, the lagging platform headline, and safety guardrails that must not move.